[SCHEDULE 13D/A] Oncology Institute, Inc. SEC Filing

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI) shareholder M33 Growth I LP filed Amendment No. 5 to its Schedule 13D to update its ownership in the company’s common stock.

The reporting persons now beneficially own 6,802,656 shares of TOI common stock, including 5,444,207 shares held by M33 Growth I LP and 1,358,449 shares issuable upon exercise of warrants with a $1.1980 per share exercise price. This represents 5.46% of TOI’s common stock, based on 98,381,340 shares outstanding as of November 6, 2025 plus the warrant shares.

On November 18, 2025, M33 Growth I LP distributed 2,488,182 shares of common stock in-kind to its limited partners, and TOI M, LLC distributed 590,892 shares in-kind to its members. Following these distributions, TOI M, LLC no longer beneficially owns any TOI common stock, while M33 Growth I LP and its general partner M33 Growth I GP LLC continue to report shared voting and dispositive power over 6,802,656 shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Oncology Institute, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

23343Q100

(CUSIP Number)

Gabriel Ling
c/o M33 Growth I LP, 888 Boylston Street, Suite 500
Boston, MA, 02199
6172045104

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/18/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 23343Q100

1

Name of reporting person

M33 Growth I LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,802,656.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,802,656.00

11

Aggregate amount beneficially owned by each reporting person

6,802,656.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.46 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

(1) This Schedule 13D is filed by M33 Growth I LP ("M33 LP"), M33 Growth I GP LLC ("M33 LLC") and TOI M, LLC ("TOI M" and, with M33 LP, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. (2) Consists of (i) 5,444,207 shares held by M33 LP and (ii) 1,358,449 shares issuable upon exercise of warrants to purchase shares of Common Stock (as defined herein) for an exercise price of $1.1980 per share ("Warrants") held by M33 LP. M33 LLC serves as the sole general partner of M33 LP and, as such, M33 LLC possesses voting and dispositive power over the shares held by M33 LP, and may be deemed to have indirect beneficial ownership of the shares held by M33 LP. (3) This percentage is calculated based upon 98,381,340 shares of the Issuer's (as defined herein) common stock outstanding as of November 6, 2025, as disclosed in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed by the Issuer with the Securities and Exchange Commission (the "SEC") on November 13, 2025 and the 1,358,449 shares issuable upon exercise of the Warrants.

SCHEDULE 13D

CUSIP No. 23343Q100

1

Name of reporting person

M33 Growth I GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,802,656.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,802,656.00

11

Aggregate amount beneficially owned by each reporting person

6,802,656.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.46 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.(2) Consists of (i) 5,444,207 shares held by M33 LP and (ii) 1,358,449 shares issuable upon exercise of Warrants held by M33 LP. M33 LLC serves as the sole general partner of M33 LP and, as such, M33 LLC possesses voting and dispositive power over the shares held by M33 LP, and may be deemed to have indirect beneficial ownership of the shares held by M33 LP. (3) This percentage is calculated based upon 98,381,340 shares of the Issuer's (as defined herein) common stock outstanding as of November 6, 2025, as disclosed in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed by the Issuer with the Securities and Exchange Commission (the "SEC") on November 13, 2025 and the 1,358,449 shares issuable upon exercise of the Warrants.

SCHEDULE 13D

CUSIP No. 23343Q100

1

Name of reporting person

TOI M, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

(1) This Schedule 13D is filed by the Reporting Persons, including TOI M, LLC. Following the distribution of shares of Common Stock reported in this Amendment No. 5, TOI M, LLC no longer beneficially owns any shares of the Issuer's Common Stock.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Oncology Institute, Inc.
(c)	Address of Issuer's Principal Executive Offices: 18000 Studebaker Road, Suite 800, Cerritos, CALIFORNIA , 90703.
Item 1 Comment: This Amendment No. 5 (the "Amendment") to Schedule 13D amends and supplements the Schedule 13D originally filed with the SEC on November 22, 2021, as amended by Amendment No. 1 filed with the SEC on July 12, 2022, Amendment No. 2 filed with the SEC on September 26, 2022, Amendment No. 3 filed with the SEC on March 28, 2025 and Amendment No. 4 filed with the SEC on September 5, 2025 (as amended, the "Schedule 13D"), on behalf of M33 Growth I LP ("M33 LP"), M33 Growth I GP LLC ("M33 LLC") and TOI M, LLC ("TOI M" and, together with M33 LP and M33 LLC, collectively, the "Reporting Persons"), relates to the common stock, $0.001 par value ("Common Stock"), of The Oncology Institute, Inc., a Delaware corporation (the "Issuer" or "TOI"). The Items below amend and supplement the information disclosed under the corresponding Items of Schedule 13D as described below. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	On November 18, 2025, M33 LP distributed 2,488,182 shares of Common Stock and TOI M distributed 590,892 shares of Common Stock, in each case, in-kind to its respective limited partners and members.
Item 4.	Purpose of Transaction
	Item 4 is hereby supplemented as follows: The information set forth in Item 3 of this Schedule 13D, as amended therein, is incorporated herein by reference.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 is hereby amended and restated as follows: (a) and (b) See Items 7-11 of the cover pages of this Statement, as amended, and Item 3 of the Schedule 13D.
(b)	Except as reported in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.
(c)	No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.
(d)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	There are no amendments or supplements to the information previously set forth in Item 6 of the Schedule 13D.
Item 7.	Material to be Filed as Exhibits.
	There are no amendments or supplements to the information previously set forth in Item 7 of the Schedule 13D

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

M33 Growth I LP

Signature:	/s/ Gabriel Ling
Name/Title:	Gabriel Ling / Managing Member
Date:	11/20/2025

M33 Growth I GP LLC

Signature:	/s/ Gabriel Ling
Name/Title:	Gabriel Ling / Managing Member
Date:	11/20/2025

TOI M, LLC

Signature:	/s/ Gabriel Ling
Name/Title:	Gabriel Ling / Managing Member
Date:	11/20/2025

FAQ

How many Oncology Institute (TOI) shares does M33 Growth I LP now beneficially own?

M33 Growth I LP and its general partner report beneficial ownership of 6,802,656 shares of Oncology Institute, Inc. common stock, representing 5.46% of the company’s common stock.

What transactions led to TOI’s Schedule 13D/A Amendment No. 5 by M33 Growth?

On November 18, 2025, M33 Growth I LP distributed 2,488,182 shares of TOI common stock in-kind to its limited partners, and TOI M, LLC distributed 590,892 shares in-kind to its members, prompting the updated ownership disclosure.

Does TOI M, LLC still own any Oncology Institute (TOI) common stock after this amendment?

No. The filing states that following the reported in-kind distribution, TOI M, LLC no longer beneficially owns any shares of Oncology Institute, Inc. common stock.

What portion of M33 Growth’s TOI position consists of warrants?

Of the 6,802,656 shares beneficially owned, 1,358,449 shares are issuable upon exercise of warrants to purchase TOI common stock at an exercise price of $1.1980 per share.

How was the 5.46% ownership percentage in Oncology Institute (TOI) calculated?

The 5.46% figure is based on 98,381,340 shares of TOI common stock outstanding as of November 6, 2025, as disclosed in TOI’s Form 10-Q, plus the 1,358,449 shares issuable upon exercise of the warrants.

Who are the reporting persons in this TOI Schedule 13D/A Amendment No. 5?

The reporting persons are M33 Growth I LP, M33 Growth I GP LLC, and TOI M, LLC. M33 Growth I GP LLC is the sole general partner of M33 Growth I LP and may be deemed to have indirect beneficial ownership of the shares held by M33 Growth I LP.